Reuters: IPOX® Associate Lukas Muehlbauer Comments on Kardigan’s Nasdaq Debut and Biotech IPO Market Trends

Reuters reported that Kardigan shares rose above their IPO price in the company’s Nasdaq debut after the Princeton, New Jersey-based heart drug developer raised $400 million in an upsized U.S. IPO. The article noted that Kardigan’s strong debut reflected renewed investor appetite for biotech companies with advanced clinical programs and promising drug pipelines.

IPOX® Research Associate Lukas Muehlbauer was quoted by Reuters on the broader recovery in biotech IPO activity, while emphasizing that the market remains more selective than during the 2020–2021 period. His commentary placed Kardigan’s offering within a reopening IPO window that is primarily benefiting companies with late-stage assets, clearer paths toward commercialization, visible clinical catalysts, or strong industry backers.

In broader unpublished commentary shared with Reuters, Muehlbauer also addressed Kardigan’s going-concern disclosure, noting that such warnings are relatively common among clinical-stage biotech companies and should be viewed in the context of why the company is raising capital. He added that while Kardigan said the IPO proceeds should fund operations into 2028, investors may still monitor the potential for follow-on offerings, particularly if favorable market conditions or positive clinical data create opportunities for additional equity raises.

“We've seen the market recover lately, with proceeds already substantially ahead of last year's levels, but this is not a return to the 2020-2021 'free-for-all', when many companies were still at very early or pre-clinical stages,” said IPOX Research Associate Lukas Muehlbauer.

“Kardigan disclosing that it wouldn't have cash reserves to fund operations for at least 12 months – this is exactly why they are raising money now,” Muehlbauer said, adding “still, investors may watch out for potential follow-on offerings as an overhang, particularly as the company said it may seek additional capital in favorable market conditions.”

In his broader commentary to Reuters, Muehlbauer added: “Overall, biotech IPOs are in their best shape in several years, but the window is mainly open for companies with visible catalysts in the foreseeable future.”

Read the full article by Aditi Tiwari and Prakhar Srivastava on Reuters: Kardigan surges in Nasdaq debut after upsized $400 million IPO